INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
HOUSE PTR/SaleVerified data

Pete Sessions sold ABBV

Self · AbbVie Inc. · AbbVie Inc. Common Stock

Side
SELL
Value range
$15K – $50K
Shares
Not disclosed
Price
—
Executed
Sep 14, 2026
Disclosed
Sep 18, 2026
Disclosure timeline4 days from execution to publication · legal deadline 45 days
Sep 14 executedSep 18, 2026 disclosed

ABBV · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type+10 / 20

    Sale

  • Relative size+6 / 25

    Disclosed range starting at $15K

  • Filing timing0 / 15

    Disclosed 4 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ABBV

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    QE
    Quaggin Susan EDirector
    ABBVAbbVie Inc.
    Grant or award
    		A$15K
    59 sh
    		Sep 30, 2026Oct 2, 2026
    traded Sep 30, 2026
    		+2dSEC FORM 4

    Evidence

    20
    Josh GottheimerDJoint
    ABBVAbbVie Inc.
    Sale
    		SELL$1,001 – $15KMay 5, 2026Jun 3, 2026
    traded May 5, 2026
    		+29dHOUSE PTR

    Evidence

    17
    DL
    Davis Jennifer L.Director
    ABBVAbbVie Inc.
    Grant or award
    		A—
    1,118 sh
    		May 8, 2026May 12, 2026
    traded May 8, 2026
    		+4dSEC FORM 4

    Evidence

    17
    QE
    Quaggin Susan EDirector
    ABBVAbbVie Inc.
    Grant or award
    		A—
    1,118 sh
    		May 8, 2026May 12, 2026
    traded May 8, 2026
    		+4dSEC FORM 4

    Evidence

    42
    PR
    Purdue David RyanSVP, Controller
    ABBVAbbVie Inc.
    Open-market sale
    		SELL$1.22M
    5,230 sh
    		Mar 4, 2026Mar 6, 2026
    traded Mar 4, 2026
    		+2dSEC FORM 4

    Evidence

    29
    CD
    Crum Demetris DEVP, CHIEF HR OFFICER
    ABBVAbbVie Inc.
    Tax withholding
    		F$370K
    1,594 sh
    		Feb 27, 2026Mar 6, 2026
    traded Feb 27, 2026
    		+7dSEC FORM 4

    Evidence

    27
    PR
    Purdue David RyanSVP, Controller
    ABBVAbbVie Inc.
    Tax withholding
    		F$625K
    2,692 sh
    		Feb 27, 2026Mar 3, 2026
    traded Feb 27, 2026
    		+4dSEC FORM 4

    Evidence

    13
    PR
    Purdue David RyanSVP, Controller
    ABBVAbbVie Inc.
    Grant or award
    		A—
    890 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    PR
    Purdue David RyanSVP, Controller
    ABBVAbbVie Inc.
    Grant or award
    		A—
    1,292 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    PR
    Purdue David RyanSVP, Controller
    ABBVAbbVie Inc.
    Grant or award
    		A—
    1,384 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PR
    Purdue David RyanSVP, Controller
    ABBVAbbVie Inc.
    Grant or award
    		A—
    4,875 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TR
    Thakkar RoopalEVP, R&D and CSO
    ABBVAbbVie Inc.
    Grant or award
    		A—
    6,015 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TR
    Thakkar RoopalEVP, R&D and CSO
    ABBVAbbVie Inc.
    Grant or award
    		A—
    2,138 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TR
    Thakkar RoopalEVP, R&D and CSO
    ABBVAbbVie Inc.
    Grant or award
    		A—
    3,346 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TR
    Thakkar RoopalEVP, R&D and CSO
    ABBVAbbVie Inc.
    Grant or award
    		A—
    6,638 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TR
    Thakkar RoopalEVP, R&D and CSO
    ABBVAbbVie Inc.
    Grant or award
    		A—
    21.9K sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    21
    SC
    Siatis Perry CEVP, GC AND SECRETARY
    ABBVAbbVie Inc.
    Grant or award
    		A—
    16.3K sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SC
    Siatis Perry CEVP, GC AND SECRETARY
    ABBVAbbVie Inc.
    Grant or award
    		A—
    5,792 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SC
    Siatis Perry CEVP, GC AND SECRETARY
    ABBVAbbVie Inc.
    Grant or award
    		A—
    5,628 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    SC
    Siatis Perry CEVP, GC AND SECRETARY
    ABBVAbbVie Inc.
    Grant or award
    		A—
    5,808 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20035480

    Timestamps

    Event (reported)
    Sep 14, 2026
    Published
    Sep 18, 2026
    Ingested by INSIDER
    Nov 4, 22:39 UTC
    Last re-read
    Nov 5, 07:36 UTC

    Extracted facts

    Filer
    Pete Sessions
    Role
    Self
    Transaction
    SaleAs filed: “S”
    Asset
    AbbVie Inc. Common Stock
    Ticker
    ABBV
    Reported value
    $15K – $50KAs filed: “$15,001 - $50,000”
    Execution date (reported)
    Sep 14, 2026
    Notification date (reported)
    Sep 18, 2026
    Days from execution to publication
    4

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $15,001
    • High: $50,000

    = $32,501

    What this establishes

    Pete Sessions reported a sale of AbbVie Inc. Common Stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Self
    Pete Sessionsbioguide:S000250
    Issuer
    AbbVie Inc.cik:0001551152

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.